| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Tick-borne diseases (TBDs) occur worldwide, but historically, only certain pockets of the United States posed a risk for infection. However, the geographic range of ticks continues to expand in North America, leading to higher risks of TBD exposure for the public. As a result of increasing exposure and the rising number of potential tick-borne pathogens, it is increasingly important to recognize who to test, when to test, and what test to use for patients who present with TBD symptoms.
We offer a full menu of individual tests and panels that aid in the diagnosis of TBDs. In addition to our comprehensive testing menu, we have developed multiple TBD testing algorithms, including modified two-tiered assays, to help guide and optimize diagnostic testing.
Serology panels
Included testing
Included testing
Molecular panel
Next-generation sequencing panel
This tick-borne assay was developed by Mayo Clinic to identify pathogenic bacteria infecting whole blood. It uses PCR and next-generation sequencing to detect and differentiate most of the tick-borne bacteria that can be present in a patient's blood sample. The assay can also detect bacteria that cause similar diseases to those of tick-borne diseases, such as leptospirosis. This assay targets a region of the 16s ribosomal RNA gene — a gene found in all bacteria — that allows us to taxonomically specifically report most of the tick-borne bacteria that may be present in a patient's blood sample. It may be useful for situations in which tick-borne bacterial infection is suspected but traditional laboratory methods have failed to yield a diagnosis.
Highlights
Bobbi Pritt, M.D., explains how Mayo Clinic Laboratories' new assay identifies less-common tick-borne bacteria in whole blood. The assay is recommended when tick-borne bacterial infection is suspected but standard testing is unrevealing.
Key testing
Highlights
Joshua Bornhorst, Ph.D., associate director of Mayo Clinic's Clinical Immunoassay Lab, explains how humans can develop an allergy to the alpha-gal molecule, and he describes a new allergen antibody test that can be used to detect it. Dr. Bornhorst also reviews other tests that should be used in conjunction with alpha-gal testing to accurately identify the scope and underlying cause of the allergy.
Key testing
Key testing
Key testing
Key testing
Key testing
Key testing
Key testing
Initial symptoms of Rocky Mountain spotted fever, which is caused by the Rickettsia rickettsii bacterium and transferred to humans through the bites of hard-bodied ticks, can be mild and non-specific. Lacking prompt and proper treatment, however, the infection can quickly progress to more severe symptoms. Including altered mental status, cerebral swelling, respiratory distress, and multi-organ damage, symptoms can lead to death if left untreated. Accurate, timely diagnosis is vital to prevent against serious harm.
Key testing